{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T14:18:10Z","timestamp":1787062690420,"version":"build-2736575974"},"reference-count":85,"publisher":"Oxford University Press (OUP)","issue":"3","license":[{"start":{"date-parts":[[2025,9,3]],"date-time":"2025-09-03T00:00:00Z","timestamp":1756857600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/pages\/standard-publication-reuse-rights"}],"funder":[{"DOI":"10.13039\/501100000024","name":"Canadian Institutes of Health Research","doi-asserted-by":"publisher","award":["PJT-175027"],"award-info":[{"award-number":["PJT-175027"]}],"id":[{"id":"10.13039\/501100000024","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000024","name":"Canadian Institutes of Health Research","doi-asserted-by":"publisher","award":["PJT-198110"],"award-info":[{"award-number":["PJT-198110"]}],"id":[{"id":"10.13039\/501100000024","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000191","name":"Kidney Foundation of Canada","doi-asserted-by":"publisher","award":["851937-21KHRG"],"award-info":[{"award-number":["851937-21KHRG"]}],"id":[{"id":"10.13039\/501100000191","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000191","name":"Kidney Foundation of Canada","doi-asserted-by":"publisher","award":["24KHRG-1251453"],"award-info":[{"award-number":["24KHRG-1251453"]}],"id":[{"id":"10.13039\/501100000191","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Lorna Jocelyn Wood Chair for Kidney Research"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,3,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Dr John Laragh, a pioneer in the field of hypertension, held a fundamental belief in the need to challenge existing dogmas in medicine to enhance our scientific understanding of disease and advance patient care. Perhaps in no area of hypertension does this ring truer with than primary aldosteronism (PA). Following its initial description in the mid-1950s with an initial surge in diagnoses soon thereafter, PA was ultimately relegated to be considered a \u201czebra\u201d of hypertension felt to be responsible for only a small percentage of cases. In turn, diagnostic and treatment pathways went largely unchanged for decades. However, recent years have witnessed a renaissance in PA sparked by a number of scientific breakthroughs that have re-fashioned many long-held paradigms. Such breakthroughs include the recognition that classically defined PA is highly prevalent and that an even broader spectrum of milder forms of dysregulated aldosterone production (subclinical PA) goes completely unrecognized in modern-day clinical practice. Further, a number of pitfalls have recently been exposed across all steps of traditional PA diagnostic pathways, explaining many prior missed cases and missed opportunities. Acknowledging these pitfalls may allow for streamlined, practical, and evidence-based algorithms in the future to enhance disease detection. Finally, treatment approaches are now evolving with new strategies to better guide existing medical therapies along with emerging novel therapeutic options which may transform PA management in the future. This review discusses these recent advances in our understanding of PA and sheds light on what the future of PA management may entail.<\/jats:p>","DOI":"10.1093\/ajh\/hpaf156","type":"journal-article","created":{"date-parts":[[2025,8,15]],"date-time":"2025-08-15T11:55:04Z","timestamp":1755258904000},"page":"331-341","source":"Crossref","is-referenced-by-count":2,"title":["Rethinking Primary Aldosteronism: The 2025 John H. Laragh Research Award"],"prefix":"10.1093","volume":"39","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-3559-3531","authenticated-orcid":false,"given":"Gregory L","family":"Hundemer","sequence":"first","affiliation":[{"name":"Department of Medicine, Division of Nephrology, University of Ottawa , Ottawa, Ontario ,","place":["Canada"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexander A","family":"Leung","sequence":"additional","affiliation":[{"name":"Department of Medicine, Division of Endocrinology and Metabolism, Cumming School of Medicine, University of Calgary , Calgary, Alberta ,","place":["Canada"]},{"name":"Department of Community Health Sciences, Cumming School of Medicine, University of Calgary , Calgary, Alberta ,","place":["Canada"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8129-9360","authenticated-orcid":false,"given":"Gregory A","family":"Kline","sequence":"additional","affiliation":[{"name":"Department of Medicine, Division of Endocrinology and Metabolism, Cumming School of Medicine, University of Calgary , Calgary, Alberta ,","place":["Canada"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2025,9,3]]},"reference":[{"key":"2026021616021868800_CIT0001","doi-asserted-by":"crossref","first-page":"1019","DOI":"10.1093\/ajh\/hpu110","article-title":"John H. Laragh, MD: clinician-scientist","volume":"27","author":"Sealey","year":"2014","journal-title":"Am J Hypertens"},{"key":"2026021616021868800_CIT0002","doi-asserted-by":"crossref","first-page":"1011","DOI":"10.1093\/ajh\/hpu106","article-title":"Tribute to John H. Laragh, MD","volume":"27","author":"Blumenfeld","year":"2014","journal-title":"Am J Hypertens"},{"key":"2026021616021868800_CIT0003","doi-asserted-by":"crossref","first-page":"1057","DOI":"10.1210\/er.2018-00139","article-title":"The expanding spectrum of primary aldosteronism: implications for diagnosis, pathogenesis, and treatment","volume":"39","author":"Vaidya","year":"2018","journal-title":"Endocr Rev"},{"key":"2026021616021868800_CIT0004","doi-asserted-by":"crossref","first-page":"149","DOI":"10.3109\/08037059209077510","article-title":"Fibrosis of the human heart and systemic organs in adrenal adenoma","volume":"1","author":"Campbell","year":"1992","journal-title":"Blood Press"},{"key":"2026021616021868800_CIT0005","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1111\/j.1749-6632.2002.tb04415.x","article-title":"The pathophysiology of aldosterone in the cardiovascular system","volume":"970","author":"Rocha","year":"2002","journal-title":"Ann N Y Acad Sci"},{"key":"2026021616021868800_CIT0006","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1291\/hypres.20.85","article-title":"Left ventricular hypertrophy is more prominent in patients with primary aldosteronism than in patients with other types of secondary hypertension","volume":"20","author":"Tanabe","year":"1997","journal-title":"Hypertens Res"},{"key":"2026021616021868800_CIT0007","doi-asserted-by":"crossref","first-page":"897","DOI":"10.1161\/HYPERTENSIONAHA.115.07074","article-title":"Aldosterone-induced vascular remodeling and endothelial dysfunction require functional angiotensin Type 1a receptors","volume":"67","author":"Briet","year":"2016","journal-title":"Hypertension"},{"key":"2026021616021868800_CIT0008","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1159\/000345243","article-title":"Vascular actions of aldosterone","volume":"50","author":"Briet","year":"2013","journal-title":"J Vasc Res"},{"key":"2026021616021868800_CIT0009","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1007\/s11906-003-0012-2","article-title":"Aldosterone: a risk factor for vascular disease","volume":"5","author":"Fritsch Neves","year":"2003","journal-title":"Curr Hypertens Rep"},{"key":"2026021616021868800_CIT0010","doi-asserted-by":"crossref","first-page":"324","DOI":"10.1161\/HYPERTENSIONAHA.111.181123","article-title":"T regulatory lymphocytes prevent aldosterone-induced vascular injury","volume":"59","author":"Kasal","year":"2012","journal-title":"Hypertension"},{"key":"2026021616021868800_CIT0011","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1161\/01.HYP.0000078357.92682.EC","article-title":"Endothelin antagonism on aldosterone-induced oxidative stress and vascular remodeling","volume":"42","author":"Pu","year":"2003","journal-title":"Hypertension"},{"key":"2026021616021868800_CIT0012","doi-asserted-by":"crossref","first-page":"2192","DOI":"10.1097\/HJH.0b013e328330a963","article-title":"Aldosterone induces arterial stiffness in absence of oxidative stress and endothelial dysfunction","volume":"27","author":"Leibovitz","year":"2009","journal-title":"J Hypertens"},{"key":"2026021616021868800_CIT0013","doi-asserted-by":"crossref","first-page":"1055","DOI":"10.1038\/ng.2716","article-title":"Somatic mutations in ATP1A1 and CACNA1D underlie a common subtype of adrenal hypertension","volume":"45","author":"Azizan","year":"2013","journal-title":"Nat Genet"},{"key":"2026021616021868800_CIT0014","doi-asserted-by":"crossref","first-page":"783","DOI":"10.1161\/HYPERTENSIONAHA.113.02234","article-title":"Role for germline mutations and a rare coding single nucleotide polymorphism within the KCNJ5 potassium channel in a large cohort of sporadic cases of primary aldosteronism","volume":"63","author":"Murthy","year":"2014","journal-title":"Hypertension"},{"key":"2026021616021868800_CIT0015","doi-asserted-by":"crossref","first-page":"e45","DOI":"10.1210\/clinem\/dgaa703","article-title":"Aldosterone is aberrantly regulated by various stimuli in a high proportion of patients with primary aldosteronism","volume":"106","author":"St-Jean","year":"2021","journal-title":"J Clin Endocrinol Metab"},{"key":"2026021616021868800_CIT0016","doi-asserted-by":"crossref","first-page":"10","DOI":"10.7326\/M20-0065","article-title":"The unrecognized prevalence of primary aldosteronism: a cross-sectional study","volume":"173","author":"Brown","year":"2020","journal-title":"Ann Intern Med"},{"key":"2026021616021868800_CIT0017","doi-asserted-by":"crossref","first-page":"1811","DOI":"10.1016\/j.jacc.2017.01.052","article-title":"Prevalence and clinical manifestations of primary aldosteronism encountered in primary care practice","volume":"69","author":"Monticone","year":"2017","journal-title":"J Am Coll Cardiol"},{"key":"2026021616021868800_CIT0018","doi-asserted-by":"crossref","first-page":"1913","DOI":"10.1016\/j.jacc.2020.02.052","article-title":"Primary aldosteronism in patients in china with recently detected hypertension","volume":"75","author":"Xu","year":"2020","journal-title":"J Am Coll Cardiol"},{"key":"2026021616021868800_CIT0019","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1016\/S2213-8587(17)30367-4","article-title":"Cardiometabolic outcomes and mortality in medically treated primary aldosteronism: a retrospective cohort study","volume":"6","author":"Hundemer","year":"2018","journal-title":"Lancet Diabetes Endocrinol"},{"key":"2026021616021868800_CIT0020","doi-asserted-by":"crossref","first-page":"658","DOI":"10.1161\/HYPERTENSIONAHA.118.11568","article-title":"Renal outcomes in medically and surgically treated primary aldosteronism","volume":"72","author":"Hundemer","year":"2018","journal-title":"Hypertension"},{"key":"2026021616021868800_CIT0021","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1016\/S2213-8587(17)30319-4","article-title":"Cardiovascular events and target organ damage in primary aldosteronism compared with essential hypertension: a systematic review and meta-analysis","volume":"6","author":"Monticone","year":"2018","journal-title":"Lancet Diabetes Endocrinol"},{"key":"2026021616021868800_CIT0022","doi-asserted-by":"crossref","first-page":"1889","DOI":"10.1210\/jc.2015-4061","article-title":"The management of primary aldosteronism: case detection, diagnosis, and treatment: an Endocrine Society Clinical Practice Guideline","volume":"101","author":"Funder","year":"2016","journal-title":"J Clin Endocrinol Metab"},{"key":"2026021616021868800_CIT0023","doi-asserted-by":"crossref","first-page":"630","DOI":"10.7326\/M17-0882","article-title":"The spectrum of subclinical primary aldosteronism and incident hypertension: a cohort study","volume":"167","author":"Brown","year":"2017","journal-title":"Ann Intern Med"},{"key":"2026021616021868800_CIT0024","doi-asserted-by":"crossref","first-page":"1835","DOI":"10.1210\/jc.2016-3867","article-title":"Renin phenotypes characterize vascular disease, autonomous aldosteronism, and mineralocorticoid receptor activity","volume":"102","author":"Hundemer","year":"2017","journal-title":"J Clin Endocrinol Metab"},{"key":"2026021616021868800_CIT0025","doi-asserted-by":"crossref","first-page":"950","DOI":"10.1161\/HYPERTENSIONAHA.116.08952","article-title":"Continuum of renin-independent aldosteronism in normotension","volume":"69","author":"Baudrand","year":"2017","journal-title":"Hypertension"},{"key":"2026021616021868800_CIT0026","doi-asserted-by":"crossref","first-page":"846","DOI":"10.1161\/01.HYP.0000258554.87444.91","article-title":"Clinical and genetic correlates of aldosterone-to-renin ratio and relations to blood pressure in a community sample","volume":"49","author":"Newton-Cheh","year":"2007","journal-title":"Hypertension"},{"key":"2026021616021868800_CIT0027","doi-asserted-by":"crossref","first-page":"1409","DOI":"10.1210\/jc.2012-3353","article-title":"Evidence of primary aldosteronism in a predominantly female cohort of normotensive individuals: a very high odds ratio for progression into arterial hypertension","volume":"98","author":"Markou","year":"2013","journal-title":"J Clin Endocrinol Metab"},{"key":"2026021616021868800_CIT0028","doi-asserted-by":"crossref","first-page":"2355","DOI":"10.1161\/CIRCULATIONAHA.120.050896","article-title":"Association of serum aldosterone and plasma renin activity with ambulatory blood pressure in African Americans: The Jackson Heart Study","volume":"143","author":"Joseph","year":"2021","journal-title":"Circulation"},{"key":"2026021616021868800_CIT0029","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1161\/HYPERTENSIONAHA.120.15006","article-title":"Serum aldosterone concentration, blood pressure, and coronary artery calcium: the multi-ethnic study of atherosclerosis","volume":"76","author":"Inoue","year":"2020","journal-title":"Hypertension"},{"key":"2026021616021868800_CIT0030","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1056\/NEJMoa033263","article-title":"Serum aldosterone and the incidence of hypertension in nonhypertensive persons","volume":"351","author":"Vasan","year":"2004","journal-title":"N Engl J Med"},{"key":"2026021616021868800_CIT0031","doi-asserted-by":"crossref","first-page":"1984","DOI":"10.1161\/HYPERTENSIONAHA.122.19134","article-title":"Cardiac structure and function across the spectrum of aldosteronism: the atherosclerosis risk in communities study","volume":"79","author":"Brown","year":"2022","journal-title":"Hypertension"},{"key":"2026021616021868800_CIT0032","doi-asserted-by":"crossref","first-page":"1205","DOI":"10.1161\/HYPERTENSIONAHA.114.03231","article-title":"Aldosterone dysregulation with aging predicts renal vascular function and cardiovascular risk","volume":"63","author":"Brown","year":"2014","journal-title":"Hypertension"},{"key":"2026021616021868800_CIT0033","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1161\/CIRCULATIONAHA.123.066389","article-title":"Subclinical primary aldosteronism and cardiovascular health: a population-based cohort study","volume":"149","author":"Hundemer","year":"2024","journal-title":"Circulation"},{"key":"2026021616021868800_CIT0034","doi-asserted-by":"crossref","first-page":"2220","DOI":"10.1210\/clinem\/dgae145","article-title":"The spectrum of dysregulated aldosterone production: an International Human Physiology Study","volume":"109","author":"Parksook","year":"2024","journal-title":"J Clin Endocrinol Metab"},{"key":"2026021616021868800_CIT0035","doi-asserted-by":"crossref","DOI":"10.1161\/CIRCULATIONAHA.124.073507","article-title":"Subclinical primary aldosteronism and major adverse cardiovascular events: a longitudinal population-based cohort study","author":"Goupil","year":"2025","journal-title":"Circulation"},{"key":"2026021616021868800_CIT0036","doi-asserted-by":"crossref","first-page":"306","DOI":"10.1161\/HYPERTENSIONAHA.124.24153","article-title":"Characterizing the origins of primary aldosteronism","volume":"82","author":"Brown","year":"2025","journal-title":"Hypertension"},{"key":"2026021616021868800_CIT0037","doi-asserted-by":"crossref","first-page":"2059","DOI":"10.1016\/S0140-6736(15)00257-3","article-title":"Spironolactone versus placebo, bisoprolol, and doxazosin to determine the optimal treatment for drug-resistant hypertension (PATHWAY-2): a randomised, double-blind, crossover trial","volume":"386","author":"Williams","year":"2015","journal-title":"Lancet"},{"key":"2026021616021868800_CIT0038","doi-asserted-by":"crossref","first-page":"464","DOI":"10.1016\/S2213-8587(18)30071-8","article-title":"Endocrine and haemodynamic changes in resistant hypertension, and blood pressure responses to spironolactone or amiloride: the PATHWAY-2 mechanisms substudies","volume":"6","author":"Williams","year":"2018","journal-title":"Lancet Diabetes Endocrinol"},{"key":"2026021616021868800_CIT0039","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1056\/NEJMoa2213169","article-title":"Phase 2 trial of baxdrostat for treatment-resistant hypertension","volume":"388","author":"Freeman","year":"2023","journal-title":"N Engl J Med"},{"key":"2026021616021868800_CIT0040","doi-asserted-by":"crossref","first-page":"1813","DOI":"10.1056\/NEJMoa2501440","article-title":"Lorundrostat efficacy and safety in patients with uncontrolled hypertension","volume":"392","author":"Laffin","year":"2025","journal-title":"N Engl J Med"},{"key":"2026021616021868800_CIT0041","doi-asserted-by":"crossref","first-page":"1140","DOI":"10.1001\/jama.2023.16029","article-title":"Aldosterone synthase inhibition with lorundrostat for uncontrolled hypertension: the Target-HTN Randomized Clinical Trial","volume":"330","author":"Laffin","year":"2023","journal-title":"JAMA"},{"key":"2026021616021868800_CIT0042","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1016\/S0895-7061(03)00867-7","article-title":"Relevance of the plasma renin hormonal control system that regulates blood pressure and sodium balance for correctly treating hypertension and for evaluating ALLHAT","volume":"16","author":"Laragh","year":"2003","journal-title":"Am J Hypertens"},{"key":"2026021616021868800_CIT0043","doi-asserted-by":"crossref","first-page":"768","DOI":"10.1001\/jamacardio.2018.2003","article-title":"Incidence of atrial fibrillation and mineralocorticoid receptor activity in patients with medically and surgically treated primary aldosteronism","volume":"3","author":"Hundemer","year":"2018","journal-title":"JAMA Cardiol"},{"key":"2026021616021868800_CIT0044","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1097\/MNH.0000000000001067","article-title":"Targeting aldosterone to improve cardiorenal outcomes: from nonsteroidal mineralocorticoid receptor antagonists to aldosterone synthase inhibitors","volume":"34","author":"Helmeczi","year":"2025","journal-title":"Curr Opin Nephrol Hypertens"},{"key":"2026021616021868800_CIT0045","doi-asserted-by":"crossref","first-page":"967","DOI":"10.1093\/ajh\/hpac079","article-title":"Primary aldosteronism: state-of-the-art review","volume":"35","author":"Vaidya","year":"2022","journal-title":"Am J Hypertens"},{"key":"2026021616021868800_CIT0046","doi-asserted-by":"crossref","first-page":"2453","DOI":"10.1210\/clinem\/dgaf284","article-title":"Primary aldosteronism: an endocrine society clinical practice guideline","volume":"110","author":"Adler","year":"2025","journal-title":"J Clin Endocrinol Metab"},{"key":"2026021616021868800_CIT0047","doi-asserted-by":"crossref","first-page":"3912","DOI":"10.1093\/eurheartj\/ehae178","article-title":"2024 ESC Guidelines for the management of elevated blood pressure and hypertension","volume":"45","author":"McEvoy","year":"2024","journal-title":"Eur Heart J"},{"key":"2026021616021868800_CIT0048","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1507\/endocrj.EJ21-0508","article-title":"Japan Endocrine Society clinical practice guideline for the diagnosis and management of primary aldosteronism 2021","volume":"69","author":"Naruse","year":"2022","journal-title":"Endocr J"},{"key":"2026021616021868800_CIT0049","doi-asserted-by":"crossref","first-page":"1269","DOI":"10.1161\/HYP.0000000000000066","article-title":"2017 ACC\/AHA\/AAPA\/ABC\/ACPM\/AGS\/APhA\/ASH\/ASPC\/NMA\/PCNA Guideline for the prevention, detection, evaluation, and management of high blood pressure in adults: executive summary: a report of the American College of Cardiology\/American Heart Association Task Force on Clinical Practice Guidelines","volume":"71","author":"Whelton","year":"2018","journal-title":"Hypertension"},{"key":"2026021616021868800_CIT0050","doi-asserted-by":"crossref","first-page":"289","DOI":"10.7326\/M20-4873","article-title":"Testing for primary aldosteronism and mineralocorticoid receptor antagonist use among U.S. Veterans: a retrospective cohort study","volume":"174","author":"Cohen","year":"2021","journal-title":"Ann Intern Med"},{"key":"2026021616021868800_CIT0051","doi-asserted-by":"crossref","first-page":"178","DOI":"10.1161\/HYPERTENSIONAHA.121.18118","article-title":"Screening rates for primary aldosteronism among individuals with hypertension plus hypokalemia: a population-based retrospective cohort study","volume":"79","author":"Hundemer","year":"2022","journal-title":"Hypertension"},{"key":"2026021616021868800_CIT0052","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1093\/ajh\/hpad022","article-title":"Screening for primary aldosteronism among hypertensive adults with obstructive sleep apnea: a retrospective population-based study","volume":"36","author":"Hundemer","year":"2023","journal-title":"Am J Hypertens"},{"key":"2026021616021868800_CIT0053","doi-asserted-by":"crossref","first-page":"977","DOI":"10.1161\/HYPERTENSIONAHA.125.24648","article-title":"Nationwide, pragmatic, direct-to-patient Primary Aldosteronism Testing Program","volume":"82","author":"Brown","year":"2025","journal-title":"Hypertension"},{"key":"2026021616021868800_CIT0054","doi-asserted-by":"crossref","first-page":"897","DOI":"10.1161\/01.HYP.0000038478.59760.41","article-title":"Drug effects on aldosterone\/plasma renin activity ratio in primary aldosteronism","volume":"40","author":"Mulatero","year":"2002","journal-title":"Hypertension"},{"key":"2026021616021868800_CIT0055","doi-asserted-by":"crossref","first-page":"681","DOI":"10.1016\/j.ecl.2019.08.002","article-title":"Primary aldosteronism diagnosis and management: a clinical approach","volume":"48","author":"Hundemer","year":"2019","journal-title":"Endocrinol Metab Clin North Am"},{"key":"2026021616021868800_CIT0056","doi-asserted-by":"crossref","first-page":"984","DOI":"10.1161\/CIRCULATIONAHA.107.708537","article-title":"Multimarker approach to evaluate the incidence of the metabolic syndrome and longitudinal changes in metabolic risk factors: the Framingham Offspring Study","volume":"116","author":"Ingelsson","year":"2007","journal-title":"Circulation"},{"key":"2026021616021868800_CIT0057","doi-asserted-by":"crossref","first-page":"2857","DOI":"10.1210\/jc.2015-1268","article-title":"Stress-induced aldosterone hyper-secretion in a substantial subset of patients with essential hypertension","volume":"100","author":"Markou","year":"2015","journal-title":"J Clin Endocrinol Metab"},{"key":"2026021616021868800_CIT0058","doi-asserted-by":"crossref","first-page":"891","DOI":"10.1161\/HYPERTENSIONAHA.120.16429","article-title":"Intraindividual variability of aldosterone concentrations in primary aldosteronism: implications for case detection","volume":"77","author":"Yozamp","year":"2021","journal-title":"Hypertension"},{"key":"2026021616021868800_CIT0059","doi-asserted-by":"crossref","first-page":"2072","DOI":"10.1161\/HYPERTENSIONAHA.124.22884","article-title":"Comparing ARR versus suppressed PRA as screening tests for primary aldosteronism","volume":"81","author":"Marcelli","year":"2024","journal-title":"Hypertension"},{"key":"2026021616021868800_CIT0060","doi-asserted-by":"crossref","first-page":"1835","DOI":"10.1161\/HYPERTENSIONAHA.122.19377","article-title":"Performance of confirmatory tests for diagnosing primary aldosteronism: a systematic review and meta-analysis","volume":"79","author":"Leung","year":"2022","journal-title":"Hypertension"},{"key":"2026021616021868800_CIT0061","doi-asserted-by":"crossref","first-page":"496","DOI":"10.1210\/clinem\/dgac654","article-title":"Exclusion Tests in Unilateral Primary Aldosteronism (ExcluPA) study","volume":"108","author":"Zhu","year":"2023","journal-title":"J Clin Endocrinol Metab"},{"key":"2026021616021868800_CIT0062","doi-asserted-by":"crossref","first-page":"948","DOI":"10.7326\/ANNALS-24-03153","article-title":"Confirmatory testing for primary aldosteronism: a study of diagnostic test accuracy","volume":"178","author":"Leung","year":"2025","journal-title":"Ann Intern Med"},{"key":"2026021616021868800_CIT0063","doi-asserted-by":"crossref","first-page":"501","DOI":"10.1210\/endrev\/bnaf007","article-title":"Subtyping of primary aldosteronism by adrenal venous sampling","volume":"46","author":"Rossi","year":"2025","journal-title":"Endocr Rev"},{"key":"2026021616021868800_CIT0064","doi-asserted-by":"crossref","first-page":"989","DOI":"10.1097\/HJH.0b013e3282f9e66a","article-title":"Adrenal vein sampling for primary aldosteronism: the assessment of selectivity and lateralization of aldosterone excess baseline and after adrenocorticotropic hormone (ACTH) stimulation","volume":"26","author":"Rossi","year":"2008","journal-title":"J Hypertens"},{"key":"2026021616021868800_CIT0065","doi-asserted-by":"crossref","first-page":"1826","DOI":"10.1210\/jc.2015-3915","article-title":"Basal and post-ACTH aldosterone and its ratios are useful during adrenal vein sampling in primary aldosteronism","volume":"101","author":"El Ghorayeb","year":"2016","journal-title":"J Clin Endocrinol Metab"},{"key":"2026021616021868800_CIT0066","doi-asserted-by":"crossref","first-page":"604","DOI":"10.1161\/HYPERTENSIONAHA.123.21910","article-title":"Multifocal, asymmetric bilateral primary aldosteronism cannot be excluded by strong adrenal vein sampling lateralization: an international retrospective cohort study","volume":"81","author":"Turcu","year":"2024","journal-title":"Hypertension"},{"key":"2026021616021868800_CIT0067","doi-asserted-by":"crossref","first-page":"637","DOI":"10.1016\/S0140-6736(24)02755-7","article-title":"Endoscopic, ultrasound-guided, radiofrequency ablation of aldosterone-producing adenomas (FABULAS): a UK, multicentre, prospective, proof-of-concept trial","volume":"405","author":"Argentesi","year":"2025","journal-title":"Lancet"},{"key":"2026021616021868800_CIT0068","doi-asserted-by":"crossref","first-page":"336","DOI":"10.7326\/ANNALS-24-00761","article-title":"Molecular imaging versus adrenal vein sampling for the detection of surgically curable primary aldosteronism: a prospective within-patient trial","volume":"178","author":"Goodchild","year":"2025","journal-title":"Ann Intern Med"},{"key":"2026021616021868800_CIT0069","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1016\/j.amjsurg.2023.10.049","article-title":"Increasing the number of surgically cured primary aldosteronism patients: the promise of simplified diagnosis and advanced nuclear adrenocortical imaging","volume":"229","author":"Kline","year":"2024","journal-title":"Am J Surg"},{"key":"2026021616021868800_CIT0070","doi-asserted-by":"crossref","first-page":"e1363","DOI":"10.1210\/clinem\/dgad542","article-title":"The promise of nuclear imaging as an alternative to adrenal venous sampling for the detection of aldosterone-producing adenomas","volume":"109","author":"Vaidya","year":"2024","journal-title":"J Clin Endocrinol Metab"},{"key":"2026021616021868800_CIT0071","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1210\/endrev\/bnad024","article-title":"Biomarkers to guide medical therapy in primary aldosteronism","volume":"45","author":"Hundemer","year":"2024","journal-title":"Endocr Rev"},{"key":"2026021616021868800_CIT0072","doi-asserted-by":"crossref","first-page":"585","DOI":"10.1161\/HYPERTENSIONAHA.117.10596","article-title":"Adrenalectomy lowers incident atrial fibrillation in primary aldosteronism patients at long term","volume":"71","author":"Rossi","year":"2018","journal-title":"Hypertension"},{"key":"2026021616021868800_CIT0073","doi-asserted-by":"crossref","first-page":"663","DOI":"10.1530\/EJE-21-0018","article-title":"Renin, a marker for left ventricular hypertrophy, in primary aldosteronism: a cohort study","volume":"185","author":"Kohler","year":"2021","journal-title":"Eur J Endocrinol"},{"key":"2026021616021868800_CIT0074","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1530\/EJE-21-0836","article-title":"Long-term mortality and cardiovascular events in patients with unilateral primary aldosteronism after targeted treatments","volume":"186","author":"Wu","year":"2021","journal-title":"Eur J Endocrinol"},{"key":"2026021616021868800_CIT0075","doi-asserted-by":"crossref","first-page":"bvab174","DOI":"10.1210\/jendso\/bvab174","article-title":"Increased dosage of MRA improves BP and urinary albumin excretion in primary aldosteronism with suppressed plasma renin","volume":"6","author":"Saiki","year":"2022","journal-title":"J Endocr Soc"},{"key":"2026021616021868800_CIT0076","doi-asserted-by":"crossref","first-page":"e023813","DOI":"10.1161\/JAHA.121.023813","article-title":"Comparison of echocardiographic changes between surgery and medication treatment in patients with primary aldosteronism","volume":"11","author":"Ueda","year":"2022","journal-title":"J Am Heart Assoc"},{"key":"2026021616021868800_CIT0077","doi-asserted-by":"crossref","first-page":"916744","DOI":"10.3389\/fendo.2022.916744","article-title":"Treatment of primary aldosteronism and reversal of renin suppression improves left ventricular systolic function","volume":"13","author":"Puar","year":"2022","journal-title":"Front Endocrinol (Lausanne)"},{"key":"2026021616021868800_CIT0078","doi-asserted-by":"crossref","first-page":"624","DOI":"10.1210\/clinem\/dgac649","article-title":"Implication of MR activity in posttreatment arterial stiffness reversal in patients with primary aldosteronism","volume":"108","author":"Chen","year":"2023","journal-title":"J Clin Endocrinol Metab"},{"key":"2026021616021868800_CIT0079","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1038\/s41440-022-01045-5","article-title":"Importance of dietary salt restriction for patients with primary aldosteronism during treatment with mineralocorticoid receptor antagonists: the potential importance of post-treatment plasma renin levels","volume":"46","author":"Yoshida","year":"2023","journal-title":"Hypertens Res"},{"key":"2026021616021868800_CIT0080","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1093\/ajh\/hpad032","article-title":"Using renin activity to guide mineralocorticoid receptor antagonist therapy in patients with low renin and hypertension","volume":"36","author":"Mansur","year":"2023","journal-title":"Am J Hypertens"},{"key":"2026021616021868800_CIT0081","doi-asserted-by":"crossref","first-page":"1909","DOI":"10.1161\/HYPERTENSIONAHA.123.21096","article-title":"Association of reversal of renin suppression with long-term renal outcome in medically treated primary aldosteronism","volume":"80","author":"Katsuragawa","year":"2023","journal-title":"Hypertension"},{"key":"2026021616021868800_CIT0082","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1016\/S2213-8587(24)00308-5","article-title":"Outcomes after medical treatment for primary aldosteronism: an international consensus and analysis of treatment response in an international cohort","volume":"13","author":"Yang","year":"2025","journal-title":"Lancet Diabetes Endocrinol"},{"key":"2026021616021868800_CIT0083","doi-asserted-by":"crossref","first-page":"102576","DOI":"10.1016\/j.eclinm.2024.102576","article-title":"Safety and efficacy of once-daily dexfadrostat phosphate in patients with primary aldosteronism: a randomised, parallel group, multicentre, phase 2 trial","volume":"71","author":"Mulatero","year":"2024","journal-title":"EClinicalMedicine"},{"key":"2026021616021868800_CIT0084","doi-asserted-by":"crossref","first-page":"515","DOI":"10.1056\/NEJMc2508629","article-title":"Phase 2a study of baxdrostat in primary aldosteronism","volume":"393","author":"Turcu","year":"2025","journal-title":"N Engl J Med"},{"key":"2026021616021868800_CIT0085","doi-asserted-by":"crossref","first-page":"637","DOI":"10.1093\/ajh\/hpaf091","article-title":"Recent advances in adrenal ablation for primary aldosteronism","volume":"38","author":"Glassman","year":"2025","journal-title":"Am J Hypertens"}],"container-title":["American Journal of Hypertension"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/ajh\/advance-article-pdf\/doi\/10.1093\/ajh\/hpaf156\/64198386\/hpaf156.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ajh\/article-pdf\/39\/3\/331\/64198386\/hpaf156.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ajh\/article-pdf\/39\/3\/331\/64198386\/hpaf156.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,2,16]],"date-time":"2026-02-16T21:02:30Z","timestamp":1771275750000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/ajh\/article\/39\/3\/331\/8246585"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,9,3]]},"references-count":85,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2025,9,3]]},"published-print":{"date-parts":[[2026,3,1]]}},"URL":"https:\/\/doi.org\/10.1093\/ajh\/hpaf156","relation":{},"ISSN":["0895-7061","1941-7225"],"issn-type":[{"value":"0895-7061","type":"print"},{"value":"1941-7225","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2026,3]]},"published":{"date-parts":[[2025,9,3]]}}}